172 related articles for article (PubMed ID: 27068870)
1. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients.
Hüser C; Dieterich P; Singh J; Shah-Hosseini K; Allekotte S; Lehmacher W; Compalati E; Mösges R
Allergy; 2017 Jan; 72(1):77-84. PubMed ID: 27068870
[TBL] [Abstract][Full Text] [Related]
2. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients.
Mösges R; Rohdenburg C; Eichel A; Zadoyan G; Kasche EM; Shah-Hosseini K; Lehmacher W; Schmalz P; Compalati E
Immunotherapy; 2017 Nov; 9(15):1225-1238. PubMed ID: 29130797
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
5. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.
Okamoto Y; Fujieda S; Okano M; Yoshida Y; Kakudo S; Masuyama K
Allergy; 2017 Mar; 72(3):435-443. PubMed ID: 27471838
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
8. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population.
Okamoto Y; Fujieda S; Okano M; Hida H; Kakudo S; Masuyama K
Pediatr Allergy Immunol; 2019 Feb; 30(1):66-73. PubMed ID: 30281866
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
13. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
14. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients.
Bozek A; Starczewska-Dymek L; Jarzab J
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):77-82. PubMed ID: 28668244
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
16. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period.
Soh JY; Thalayasingam M; Ong S; Loo EX; Shek LP; Chao SS
J Laryngol Otol; 2016 Mar; 130(3):272-7. PubMed ID: 26781592
[TBL] [Abstract][Full Text] [Related]
17. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.
Devillier P; Fadel R; de Beaumont O
Allergy; 2016 Feb; 71(2):249-57. PubMed ID: 26465232
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.
Zieglmayer P; Nolte H; Nelson HS; Bernstein DI; Kaur A; Jacobi H; Lemell P; Schmutz R; Zieglmayer R; Horak F
Ann Allergy Asthma Immunol; 2016 Dec; 117(6):690-696.e1. PubMed ID: 27979028
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK
J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study.
Okamiya K; Sekino H; Azuma R; Kudo M; Sakaguchi M; Nemoto F; Muramatsu N; Maekawa Y; Tanaka A
J Asthma; 2019 Dec; 56(12):1347-1355. PubMed ID: 30444150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
